Injection Pen Market By Product, Application, End-Users, Pen Accessories, Dosage, & Region for 2024-2031

The injection pen market is expanding significantly due to the increasing prevalence of chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis. These illnesses frequently necessitate regular, exact amounts of medication which can be challenging to administer with conventional syringes. Injection pens make the process considerably easier. They are intended to be user-friendly allowing patients to self-administer medication with minimal discomfort and effort. The pens come pre-filled with medication and feature changeable dose settings making them easy and lowering the chance of dosing errors by enabling the market to surpass a revenue of USD 1.90 Billion valued in 2024 and reach a valuation of around USD 2.58 Billion by 2031.

Advancements in technology are making injection pens even more appealing. Manufacturers are developing smart pens that can connect to mobile apps providing patients with reminders and tracking their medication usage. These features help improve adherence to treatment regimens which is crucial for managing chronic diseases effectively. Additionally, the growing trend towards home healthcare and the increasing preference for minimally invasive treatments are boosting the adoption of injection pens by enabling the market to grow at a CAGR of 3.90% from 2024 to 2031.

Injection Pen Market: Definition/ Overview

Injection pen is a medical gadget used to provide precise amounts of medication via a needle. It resembles a huge pen and is intended to make the procedure of injecting drugs simpler and more convenient for patients. Injection pens are frequently used to provide medications such as insulin for diabetes, growth hormones, and some treatments for autoimmune disorders such as rheumatoid arthritis.

The use of injectable pens has transformed treatment regimens by increasing patient compliance while decreasing the fear and discomfort associated with traditional syringe injections. For diabetic patients, these pens provide a simple way to manage blood sugar levels enabling a more independent lifestyle. Precision in dose distribution contributes to drug consumption consistency which is critical for preserving health and avoiding issues. Furthermore, healthcare personnel benefit from the pens simplicity which streamlines the administration process and reduces the possibility of errors.

Injection pens are likely to become increasingly important in healthcare. One notable trend is their ongoing development in usability and automation. Future injectable pens may have even simpler mechanisms lowering the number of steps necessary for administration and making them available to a broader spectrum of patients. Furthermore, advances in materials and technology are projected to improve their precision and dependability providing constant dosage distribution and reducing discomfort during injection procedures.

Will the Increasing Technological Advancements Drive the Injection Pen Market?

Insulin pens offer various advantages over traditional methods of insulin delivery such as vials and syringes. They are intended to be easier and more convenient for patients. Unlike syringes which must be drawn from a vial and then injected, insulin pens are pre-filled with insulin cartridges. This makes them easier to use particularly for patients who require insulin several times per day. Users find them more rewarding because they are less bulky, inconspicuous, and portable making diabetes management easier in a variety of social situations. One major advantage of insulin pens is their ease of usage. Many contemporary versions are meant to be user-friendly requiring little instruction.

The development of injection devices such as autoinjectors and bolus pump-based systems demonstrates this dedication. These devices are intended to provide alternate methods of delivering pharmaceuticals including insulin, and are evaluated on their capacity to dispense drugs safely and effectively while increasing patient compliance.

The emergence of injection devices like as insulin pens, autoinjectors, and bolus pump-based systems represents a huge step forward in healthcare technology. These improvements not only make it easier and more comfortable for patients to manage chronic illnesses but they also help to enhance treatment regimen adherence. As technology advances, the future promises increasingly more complex and individualized solutions to satisfy the different requirements of patients around the world.

Will Alternative Modes of Drug Delivery Hamper the Injection Pen Market?

Alternative forms of medication delivery may have an impact on the injectable pen business but this relies on a number of circumstances. Alternative techniques include oral pills, patches, inhalers, and more recent technology such as implanted devices or microneedles. Each of these methods provides distinct benefits such as convenience, reduced pain, or extended medication release which may appeal to patients who find injections difficult or inconvenient. Oral drugs, for example, are popular due to their simplicity and non-invasiveness. Many people choose to ingest pills rather than use injectable pens. This method of distribution is especially useful for pharmaceuticals that can be absorbed via the digestive system without degradation. Similarly, transdermal patches allow continuous medication release through the skin, ensuring stable blood levels and eliminating

Alternative forms of medication delivery offer viable solutions with their own set of benefits but injectable pens remain popular because to their proven effectiveness, ease, and continual technical developments. The precise drug, patient preferences, and type of the medical condition are frequently used to determine whether to use injectable pens or other techniques. As healthcare evolves, the injectable pen industry is likely to adapt and innovate ensuring its place among the variety of medication delivery methods available to patients.

Category-Wise Acumens

How Convenience and Ease of Use Drive the Product Segment?

Disposable injection pens is projected to hold major share in the market. This domination stems mostly from the convenience and ease of usage provided by disposable pens. Patients prefer them since they do not require maintenance, cleaning, or the trouble of changing cartridges. These pens are simply thrown after use which is especially useful for people who may struggle to keep a reusable pen in good condition or who want a simple, one-time-use option. This simplicity and user-friendliness increase their popularity among patients resulting in increased adoption rates.

Disposable injectable pens are popular in the healthcare business because they minimize the danger of contamination and infection. Because each pen is only used once, there is less risk of poor cleaning or reuse which can lead to hygiene problems. This makes disposable pens a safer option particularly for frequently injected drugs such as insulin for diabetes. Furthermore, the pharmaceutical industry's emphasis on patient safety and adherence has resulted in the creation of more complex disposable pens including dose memory, automatic needle retraction, and ergonomic designs. These advancements improve the user experience making disposable pens the preferable option. The combination of convenience, safety, and constant innovation has secured the leading position of disposable injection pens in the market.

How do Increasing Awareness and Diagnosis of Diabetes Drive the Application Segment?

The diabetic category dominates the injectable pen market. This dominance stems primarily from the high prevalence of diabetes globally and the need for regular insulin therapy among diabetic individuals. Insulin pens provide diabetics a convenient, accurate, and user-friendly way to manage their condition. Unlike traditional syringes, insulin pens are simple to use, portable, and engineered to provide exact insulin dosages which are critical for keeping blood sugar levels within a specific range. Diabetes therapy necessitates frequently daily injections, therefore demand for insulin pens stays constantly high contributing to the segment's market domination.

As diabetes knowledge and diagnosis have increased so has the number of patients who require insulin therapy. This has fueled innovation and advancements in injectable pen technology making them more accessible and effective for patients. Companies are constantly creating pens with advanced features including digital displays, memory functions, and dose adjusting mechanisms to improve user experience and adherence to therapy. These improvements together with the chronic nature of diabetes and insulin's critical role in its care ensure that the diabetes application category remains the largest and most influential in the injection pen market.

Gain Access into Injection Pen Market Report Methodology

Country/Region-wise Acumens

How Advancement's in Drug Delivery Technology Drive the Market in North America?

North America is expected to hold major share in the market for injectable pens owing to the rising prevalence of chronic diseases and higher healthcare expenditures in the region. Several important reasons are driving the injection pen market including the rising prevalence of chronic diseases and the growing need for user-friendly medication delivery systems.

According to the International Diabetes Federation, the number of individuals with diabetes is anticipated to increase from 537 million in 2021 to 783 million by 2045. This tendency is especially noteworthy in regions like North America where diabetes is common. For example, the US Centers for Disease Control and Prevention (CDC) estimated that approximately 34.2 million people in the United States had diabetes in 2020.

According to the Centers for Disease Control and Prevention, around 34.2 million individuals in the United States have diabetes in 2020 with another 88 million having pre-diabetes. The growing awareness of new drug delivery devices, the widespread availability of injection pens and cartridges, and the emphasis on patient-centered treatment have all contributed to the rise of the North American injection pen industry.

How Growing Awareness about Advanced Medication Delivery Devices Drive the Market in Asia Pacific Region?

Asia Pacific is expected to be the fastest-growing region in the injection pen market owing to the rising incidence of chronic diseases. Also, the rising healthcare spending is upsurging awareness of improved medicine delivery systems, thereby enhancing the sales of injection pen. The rising prevalence of chronic diseases such as cancer, cardiovascular disease, and autoimmune disorders among the Asian Pacific population owing to poor eating habits, physical inactivity, and increasing alcohol consumption is expected to drive demand for injection pens in the region. Furthermore, pharmaceutical makers increasing investments in the research of new pharmaceuticals as well as the increased emphasis on patient-centered care are helping to drive growth in the Asia Pacific injection pen market.

Technological developments in injection pen design such as the incorporation of smart features and increased dosing precision have also contributed significantly to market expansion. These innovations have improved patient adherence and safety making injectable pens more desirable to both physicians and patients. Furthermore, rising healthcare costs and greater awareness of improved pharmaceutical administration methods have accelerated the global usage of injection pens.

Competitive Landscape

The injection pen market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the injection pen market include:

Novo Nordisk A/S

Medtronic plc

Becton, Dickinson and Company

Sanofi

Eli Lilly and Company

Merck

AstraZeneca

Hoffmann-La Roche Ltd.

Owen Mumford Ltd

Ypsomed AG

Terumo Medical Corporation

Braun Medical

Sun Pharmaceutical Industries Ltd.

Latest Developments

In April 2021, Roche Diabetes Care France and BioCorp will debut the Mallya smart insulin pen device in France.

In March 2022, Novo Nordisk announced its first smart insulin pens. The NovoPen Echo Plus and NovoPen 6 are insulin self-injection pens that gather data, such as how much and when insulin is administered, and then upload it to an app via a near-field communication (NFC) link for healthcare professionals and patients to review.

Product Code: 26272

1 INTRODUCTION

1.1 MARKET DEFINITION
1.2 MARKET SEGMENTATION
1.3 RESEARCH TIMELINES
1.4 ASSUMPTIONS
1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

2.1 DATA MINING
2.2 SECONDARY RESEARCH
2.3 PRIMARY RESEARCH
2.4 SUBJECT MATTER EXPERT ADVICE
2.5 QUALITY CHECK
2.6 FINAL REVIEW
2.7 DATA TRIANGULATION
2.8 BOTTOM-UP APPROACH
2.9 TOP-DOWN APPROACH
2.10 RESEARCH FLOW
2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

3.1 GLOBAL INJECTION PEN MARKET OVERVIEW
3.2 GLOBAL INJECTION PEN ESTIMATES AND FORECAST (USD MILLION), 2021-2030
3.3 GLOBAL INJECTION PEN ECOLOGY MAPPING
3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
3.5 GLOBAL INJECTION PEN ABSOLUTE MARKET OPPORTUNITY
3.6 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY REGION
3.7 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT
3.8 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
3.9 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY DOSAGE
3.10 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY END-USERS
3.11 GLOBAL INJECTION PEN MARKET ATTRACTIVENESS ANALYSIS, BY PEN ACCESSORIES
3.12 GLOBAL INJECTION PEN MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
3.13 GLOBAL INJECTION PEN MARKET, BY PRODUCT (USD MILLION)
3.14 GLOBAL INJECTION PEN MARKET, BY APPLICATION (USD MILLION)
3.15 GLOBAL INJECTION PEN MARKET, BY DOSAGE (USD MILLION)
3.16 GLOBAL INJECTION PEN MARKET, BY END-USERS (USD MILLION)
3.17 GLOBAL INJECTION PEN MARKET, BY PEN ACCESSORIES (USD MILLION)
3.18 GLOBAL INJECTION PEN MARKET, BY GEOGRAPHY (USD MILLION)
3.19 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

4.1 GLOBAL INJECTION PEN MARKET EVOLUTION
4.2 INJECTION PEN MARKET OUTLOOK
4.3 MARKET DRIVERS
- 4.3.1 RISING PREVALENCE OF CHRONIC DISEASES
- 4.3.2 INCREASING GERIATRIC POPULATION
4.4 MARKET RESTRAINTS
- 4.4.1 HIGH COST OF INJECTION PENS
- 4.4.2 NEEDLE-STICK INJURIES AND MISUSE
4.5 MARKET TRENDS
- 4.5.1 TECHNOLOGICAL ADVANCEMENTS
- 4.5.2 RISING POPULARITY OF SELF-ADMINISTRATION OF DRUGS
4.6 MARKET OPPORTUNITY
- 4.6.1 CAPITALIZING ON BIODEGRADABLE PEN MATERIALS
- 4.6.2 EXPANSION INTO EMERGING MARKET
4.7 PORTER'S FIVE FORCES ANALYSIS
- 4.7.1 THREAT OF NEW ENTRANTS
- 4.7.2 THREAT OF SUBSTITUTES
- 4.7.3 BARGAINING POWER OF SUPPLIERS
- 4.7.4 BARGAINING POWER OF BUYERS
- 4.7.5 COMPETITIVE RIVALRY
4.8 MACROECONOMIC ANALYSIS
4.9 VALUE CHAIN ANALYSIS
4.10 PRICING ANALYSIS
4.11 ANALYSIS ON ACCESSORY CASES FOR INJECTION PENS
4.12 GLOBAL OBESITY OUTLOOK
4.13 GLP-1RA ADOPTION IN INJECTION PENS AND ITS IMPACT ON DIABETICS AND OBESITY
4.14 GROWTH HARMONE DEFICIENCY AND ITS MARKET TRENDS
4.15 LIST OF TOP INJECTION PENS

5 MARKET, BY PRODUCT

5.1 OVERVIEW
5.2 GLOBAL INJECTION PEN MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT
5.3 DISPOSABLE
5.4 REUSABLE

6 MARKET, BY DOSAGE

6.1 OVERVIEW
6.2 GLOBAL INJECTION PEN MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY DOSAGE
6.3 FIXED
6.4 VARIABLE

7 MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 GLOBAL INJECTION PEN MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
7.3 DIABETES
7.4 ANAPHYLAXIS
7.5 OSTEOPOROSIS
7.6 GROWTH HORMONE DEFICIENCY
7.7 ARTHRITIS
7.8 OTHERS

8 MARKET, BY END USERS

8.1 OVERVIEW
8.2 GLOBAL INJECTION PEN MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END USERS
8.3 HOSPITALS & DIAGNOSTIC CENTERS
8.4 HOMECARE

9 MARKET, BY PEN ACCESSORIES

9.1 OVERVIEW
9.2 PEN NEEDLE TIPS
9.3 NEEDLE COVERS OR SHIELDS
9.4 CARRY CASES
9.5 PEN GRIPS OR HOLDERS

10 MARKET, BY GEOGRAPHY

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 NORTH AMERICA MARKET SNAPSHOT
- 10.2.2 U.S.
- 10.2.3 CANADA
- 10.2.4 MEXICO
10.3 EUROPE
- 10.3.1 EUROPE MARKET SNAPSHOT
- 10.3.2 GERMANY
- 10.3.3 U.K.
- 10.3.4 FRANCE
- 10.3.5 ITALY
- 10.3.6 SPAIN
- 10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
- 10.4.1 ASIA PACIFIC MARKET SNAPSHOT
- 10.4.2 CHINA
- 10.4.3 JAPAN
- 10.4.4 INDIA
- 10.4.5 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
- 10.5.1 LATIN AMERICA MARKET SNAPSHOT
- 10.5.2 BRAZIL
- 10.5.3 ARGENTINA
- 10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST AND AFRICA
- 10.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
- 10.6.2 UAE
- 10.6.3 SAUDI ARABIA
- 10.6.4 SOUTH AFRICA
- 10.6.5 REST OF MIDDLE EAST AND AFRICA

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 KEY DEVELOPMENT
11.3 COMPANY MARKET RANKING ANALYSIS
11.4 COMPANY REGIONAL FOOTPRINT
11.5 ACE MATRIX
- 11.5.1 ACTIVE
- 11.5.2 CUTTING EDGE
- 11.5.3 EMERGING
- 11.5.4 INNOVATORS

12 GLOBAL INJECTION PEN MARKET COMPANY PROFILES

12.1 ELI LILLY AND COMPANY
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 COMPANY INSIGHTS
- 12.1.3 PRODUCT BENCHMARKING
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 WINNING IMPERATIVES
- 12.1.6 CURRENT FOCUS & STRATEGIES
- 12.1.7 SWOT ANALYSIS
- 12.1.8 THREAT FROM COMPETITION
12.2 SANOFI SA
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 COMPANY INSIGHTS
- 12.2.3 PRODUCT BENCHMARKING
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 WINNING IMPERATIVES
- 12.2.7 CURRENT FOCUS & STRATEGIES
- 12.2.8 THREAT FROM COMPETITION
12.3 NOVO NORDISK A/S
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 COMPANY INSIGHTS
- 12.3.3 PRODUCT BENCHMARKING
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 WINNING IMPERATIVES
- 12.3.6 CURRENT FOCUS & STRATEGIES
- 12.3.7 SWOT ANALYSIS
- 12.3.8 THREAT FROM COMPETITION
12.4 MERCK KGAA
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 COMPANY INSIGHTS
- 12.4.3 PRODUCT BENCHMARKING
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 WINNING IMPERATIVES
- 12.4.6 CURRENT FOCUS & STRATEGIES
- 12.4.7 THREAT FROM COMPETITION
12.5 TEVA PHARMACEUTICALS INDUSTRIES LTD.
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 COMPANY INSIGHTS
- 12.5.3 PRODUCT BENCHMARKING
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 WINNING IMPERATIVES
- 12.5.6 CURRENT FOCUS & STRATEGIES
- 12.5.7 THREAT FROM COMPETITION
12.6 OWEN MUMFORD
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 COMPANY INSIGHTS
- 12.6.3 PRODUCT BENCHMARKING
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 WINNING IMPERATIVES
- 12.6.6 CURRENT FOCUS & STRATEGIES
- 12.6.7 THREAT FROM COMPETITION
12.7 HASELMEIER GMBH
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 COMPANY INSIGHTS
- 12.7.3 PRODUCT BENCHMARKING
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 WINNING IMPERATIVES
- 12.7.6 CURRENT FOCUS & STRATEGIES
- 12.7.7 THREAT FROM COMPETITION
12.8 GERRESHEIMER AG
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 COMPANY INSIGHTS
- 12.8.3 PRODUCT BENCHMARKING
- 12.8.4 WINNING IMPERATIVES
- 12.8.5 CURRENT FOCUS & STRATEGIES
- 12.8.6 THREAT FROM COMPETITION
12.9 BIOCON LIMITED
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 COMPANY INSIGHTS
- 12.9.3 PRODUCT BENCHMARKING
- 12.9.4 WINNING IMPERATIVES
- 12.9.5 CURRENT FOCUS & STRATEGIES
- 12.9.6 THREAT FROM COMPETITION
12.10 BD (BECKTON DISCKINSON CO)
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 COMPANY INSIGHTS
- 12.10.3 PRODUCT BENCHMARKING
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 WINNING IMPERATIVES
- 12.10.6 CURRENT FOCUS & STRATEGIES
- 12.10.7 THREAT FROM COMPETITION
12.11 ASTRAZENECA
- 12.11.1 COMPANY OVERVIEW
- 12.11.2 COMPANY INSIGHTS
- 12.11.3 PRODUCT BENCHMARKING
- 12.11.4 WINNING IMPERATIVES
- 12.11.5 CURRENT FOCUS & STRATEGIES
- 12.11.6 THREAT FROM COMPETITION
12.12 SHL MEDICAL
- 12.12.1 COMPANY OVERVIEW
- 12.12.2 COMPANY INSIGHTS
- 12.12.3 PRODUCT BENCHMARKING
- 12.12.4 KEY DEVELOPMENTS
- 12.12.5 WINNING IMPERATIVES
- 12.12.6 CURRENT FOCUS & STRATEGIES
- 12.12.7 THREAT FROM COMPETITION
12.13 NOVARTIS AG
- 12.13.1 COMPANY OVERVIEW
- 12.13.2 COMPANY INSIGHTS
- 12.13.3 PRODUCT BENCHMARKING
- 12.13.4 KEY DEVELOPMENTS
- 12.13.5 WINNING IMPERATIVES
- 12.13.6 CURRENT FOCUS & STRATEGIES
- 12.13.7 THREAT FROM COMPETITION
12.14 SOLTEAM INCORPORATION CO., LTD.
- 12.14.1 COMPANY OVERVIEW
- 12.14.2 COMPANY INSIGHTS
- 12.14.3 PRODUCT BENCHMARKING
- 12.14.4 KEY DEVELOPMENTS
- 12.14.5 WINNING IMPERATIVES
- 12.14.6 CURRENT FOCUS & STRATEGIES
- 12.14.7 THREAT FROM COMPETITION
12.15 YPSOMED AG
- 12.15.1 COMPANY OVERVIEW
- 12.15.2 COMPANY INSIGHTS
- 12.15.3 PRODUCT BENCHMARKING
- 12.15.4 KEY DEVELOPMENTS
- 12.15.5 WINNING IMPERATIVES
- 12.15.6 CURRENT FOCUS & STRATEGIES
- 12.15.7 THREAT FROM COMPETITION
12.16 ROCHE HOLDING AG
- 12.16.1 COMPANY OVERVIEW
- 12.16.2 COMPANY INSIGHTS
- 12.16.3 PRODUCT BENCHMARKING
- 12.16.4 KEY DEVELOPMENTS
- 12.16.5 WINNING IMPERATIVES
- 12.16.6 CURRENT FOCUS & STRATEGIES
- 12.16.7 THREAT FROM COMPETITION
12.17 NORDIC PHARMA
- 12.17.1 COMPANY OVERVIEW
- 12.17.2 COMPANY INSIGHTS
- 12.17.3 PRODUCT BENCHMARKING
- 12.17.4 KEY DEVELOPMENTS
- 12.17.5 WINNING IMPERATIVES
- 12.17.6 CURRENT FOCUS & STRATEGIES
- 12.17.7 THREAT FROM COMPETITION
12.18 PHILLIPS-MEDISIZE CORPORATION (A MOLEX COMPANY)
- 12.18.1 COMPANY OVERVIEW
- 12.18.2 COMPANY INSIGHTS
- 12.18.3 PRODUCT BENCHMARKING
- 12.18.4 KEY DEVELOPMENTS
- 12.18.5 WINNING IMPERATIVES
- 12.18.6 CURRENT FOCUS & STRATEGIES
- 12.18.7 THREAT FROM COMPETITION
12.19 MEDTRONIC
- 12.19.1 COMPANY OVERVIEW
- 12.19.2 COMPANY INSIGHTS
- 12.19.3 PRODUCT BENCHMARKING
- 12.19.4 KEY DEVELOPMENTS
- 12.19.5 WINNING IMPERATIVES
- 12.19.6 CURRENT FOCUS & STRATEGIES
- 12.19.7 THREAT FROM COMPETITION

13 GLOBAL INJECTION PEN ACCESSORIES MARKET COMPANY PROFILES

13.1 DIABETES EXPRESS
- 13.1.1 COMPANY OVERVIEW
- 13.1.2 COMPANY INSIGHTS
- 13.1.3 PRODUCT BENCHMARKING
13.2 DIABETICWAREHOUSE
- 13.2.1 COMPANY OVERVIEW
- 13.2.2 COMPANY INSIGHTS
- 13.2.3 PRODUCT BENCHMARKING
13.3 4ALLFAMILY
- 13.3.1 COMPANY OVERVIEW
- 13.3.2 COMPANY INSIGHTS
- 13.3.3 PRODUCT BENCHMARKING